{"prompt": "['The VWDMin Trial', 'Version v1.0', 'Protocol PRO15070638', 'March 19, 2018', '10', 'SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS', '10.1 REGULATORY, ETHICAL, AND STUDY OVERSIGHT CONSIDERATION', '10.1.1 INFORMED CONSENT PROCESS', 'In obtaining and documenting informed consent, the investigator must comply with applicable regulatory', 'requirements (e.g., 45 CFR Part 46, 21 CFR Part 50, 21 CFR Part 56) and should adhere to ICH GCP. Prior', \"to the beginning of the trial, the investigator should have the IRB's written approval for the protocol and\", 'the written informed consent form(s) and any other written information to be provided to the', 'participants.', '10.1.1.1 CONSENT/ASSENT AND OTHER INFORMATIONAL DOCUMENTS PROVIDED TO', 'PARTICIPANTS', 'Consent forms that describe in detail the study intervention, study procedures, and risks will be given to', 'the study subject. Written documentation of informed consent is required prior to starting or', 'administering a study intervention.', '10.1.1.2 CONSENT PROCEDURES AND DOCUMENTATION', \"Informed consent is a process that is initiated prior to the individual's agreeing to participate in the study\", \"and continues throughout the individual's study participation. Consent forms will be Institutional Review\", 'Board (IRB)-approved and the participant will be asked to read and review the document. The investigator', 'will explain the research study to the subject and answer any questions that may arise. A verbal', \"explanation will be provided in terms suited to the subject's comprehension of the purposes, procedures,\", 'and potential risks of the study and of their rights as research participants. Subjects will have the', 'opportunity to carefully review the written consent form and ask questions prior to signing. The subjects', 'should have the opportunity to discuss the study with their family or surrogates or think about it prior to', 'agreeing to participate. The subject will sign the informed consent document prior to any procedures', 'being done specifically for the study. Subjects must be informed that participation is voluntary and that', 'they may withdraw from the study at any time, without prejudice. A copy of the informed consent', 'document will be given to study subjects for their records. The informed consent process will be', 'conducted and documented in the source document (including the date), and the form signed, before the', 'participant undergoes any study-specific procedures. The rights and welfare of the subjects will be', 'protected by emphasizing to them that the quality of their medical care will not be adversely affected if', 'they decline to participate in this study.', '10.1.2 STUDY DISCONTINUATION AND CLOSURE', 'This study may be temporarily suspended or prematurely terminated if there is sufficient reasonable', 'cause. Written notification, documenting the reason for study suspension or termination, will be provided', '37']['The VWDMin Trial', 'Version v1.0', 'Protocol PRO15070638', 'March 19, 2018', 'by the suspending or terminating party to study participants, investigator, University of Pittsburgh,', 'participating institutions, and NHLBI. If the study is prematurely terminated or suspended, the Principal', 'Investigator (PI) will promptly inform study participants, the Institutional Review Board (IRB), and sponsor', 'and will provide the reason(s) for the termination or suspension. Study participants will be contacted, as', 'applicable, and be informed of changes to study visit schedule.', 'Circumstances that may warrant termination or suspension include, but are not limited to:', 'Determination of unexpected, significant, or unacceptable risk to participants', 'Demonstration of efficacy that would warrant stopping', 'Insufficient compliance to protocol requirements', 'Data that are not sufficiently complete and/or evaluable', 'Determination that the primary endpoint has been met', 'Determination of futility', 'Study may resume once concerns about safety, protocol compliance, and data quality are addressed, and', 'satisfy the sponsor, IRB and/or Food and Drug Administration (FDA).', '10.1.3 CONFIDENTIALITY AND PRIVACY', 'Study participation and related data will be protected to maintain confidentiality. There is a possibility', \"that the subject's personal information or genetic material could become generally known. This\", 'information could impact future insurability, employability, or reproduction plans, or have a negative', 'impact on family relationships, and/or result in paternity suits or stigmatization. In order to reduce risks', 'of disclosure or breach of confidentiality, the research related documents, blood samples and clinical', 'information stored in subject research files will be assigned an alphanumeric (letters and numbers)', 'identifier (that do not contain personal identifiers). For this study, a linkage key for linking this number', \"and the subject's name will be kept at HTCs under lock and key by the principal investigator and research\", 'staff. Any publication arising from this study will not contain names or other identification unless study', 'subjects grant permission in another signed consent.', 'Participant confidentiality and privacy is strictly held in trust by the participating investigators, their staff,', 'and the sponsors and their interventions. This confidentiality is extended to cover testing of biological', 'samples and genetic tests in addition to the clinical information relating to participants. Therefore, the', 'study protocol, documentation, data, and all other information generated will be held in strict confidence.', 'No information concerning the study or the data will be released to any unauthorized third party without', 'prior written approval of the sponsor.', 'The study monitor, other authorized representatives of the sponsor, representatives of the Institutional', 'Review Board (IRB), regulatory agencies or pharmaceutical company supplying study product may inspect', 'all documents and records required to be maintained by the investigator, including but not limited to,', 'medical records (office, clinic, or hospital) and pharmacy records for the participants in this study, but', '38']\n\n###\n\n", "completion": "END"}